Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.
- Australian patent accepted for PromarkerEndo diagnostic test
- Patent protection expected until March 2041
- Test offers accurate, non-invasive diagnosis of endometriosis
- Patent complements granted protections in US and Japan
- Company pursuing further patents across multiple global jurisdictions
Australian Patent Boosts Commercial Prospects
Proteomics International Laboratories Ltd (ASX:PIQ) has secured a notice of acceptance from IP Australia for its patent covering PromarkerEndo, the company’s proprietary blood test designed to diagnose endometriosis. This milestone marks a significant step in safeguarding the company’s intellectual property within its home market, underpinning efforts to commercialise the test locally and internationally.
The patent protects methods for diagnosing endometriosis through specific protein biomarkers detected in blood samples, as well as using these results to guide treatment decisions. Subject to final grant and maintenance, this protection is expected to extend until March 2041, offering a long runway for commercial exploitation.
Addressing a Major Healthcare Gap
Endometriosis affects roughly one in nine women and is notoriously difficult to diagnose, with current methods relying on invasive surgery and an average diagnostic delay of seven years. PromarkerEndo aims to change this by providing a non-invasive, blood-based test with demonstrated high accuracy in published clinical studies, including for early-stage disease detection.
By enabling earlier and more accurate diagnosis, the test has the potential to improve patient outcomes and reduce healthcare costs, addressing a significant unmet need in women’s health.
Global Patent Strategy in Motion
Australia joins Japan and the United States as key jurisdictions where Proteomics International has secured patent protection for PromarkerEndo. The company is actively pursuing patent applications in Canada, China, Europe, India, Singapore, and South Korea, reflecting a strategic push to establish a global intellectual property footprint for this technology.
These patents are essential to the company’s commercialisation pathway, enabling potential partnerships, licensing deals, and market access in multiple regions.
Commercialisation and Market Opportunity
CEO David Morris highlighted the importance of securing patent protection in Australia as a critical step in the company’s global commercialisation strategy. The local market represents a significant opportunity for PromarkerEndo, with growing demand for innovative, non-invasive diagnostics that can improve care and reduce costs.
Proteomics International’s recent strategic moves, including a three-year exclusive distribution deal with Healius, aim to leverage established pathology networks to roll out Promarker tests nationally from FY27, supporting the commercial launch of this and other diagnostics.
Bottom Line?
The Australian patent acceptance cements a vital piece of Proteomics International’s commercialisation puzzle, but the real test will be translating intellectual property into widespread clinical adoption and partnerships.
Questions in the middle?
- How quickly will Proteomics International convert patent protection into commercial revenues in Australia?
- What progress will the company make securing patents in other key jurisdictions like Europe and China?
- Will PromarkerEndo’s clinical accuracy translate into reimbursement and adoption by healthcare providers?